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ABSTRACT: The success of cancer treatment depends on
the response to chemotherapeutic agents. However, malig-
nancies often acquire resistance to drugs if they are used
frequently. Combination therapy involving both a chemo-
therapeutic agent and molecularly targeted therapy may have
the ability to retain and enhance therapeutic efficacy. Here, we
addressed this issue by examining the efficacy of a novel
therapeutic strategy that combines AICAR and DOX within a
multifunctional platform. In this context, we reported the
bottom-up synthesis of Fe3O4@SiO2(FITC)-FA/AICAR/
DOX multifunctional nanoparticles aiming to neutralize
survivin (BIRC5) to potentiate the efficacy of DOX against
chemoresistance. The structure of nanoparticles was charac-
terized by dynamic light scattering (DLS), zeta-potential measurement, X-ray diffraction (XRD), Fourier transform infrared
spectroscopy (FT-IR), thermogravimetric analysis (TGA), and electron microscopy (SEM and STEM with EDX) techniques.
Cellular uptake and cytotoxicity experiments demonstrated preferentially targeted delivery of nanoparticles and an efficient
reduction of cancer cell viability in five different tumor-derived cell lines (A549, HCT-116, HeLa, Jurkat, and MIA PaCa-2).
These results indicate that the multifunctional nanoparticle system possesses high inhibitory drug association and sustained
cytotoxic effect with good biocompatibility. This novel approach which combines AICAR and DOX within a single platform
might be promising as an antitumor treatment for cancer.
■ INTRODUCTION
Chemotherapy is one of the principal modes of treatment for
cancer, but the effectiveness of chemotherapy is limited by drug
resistance.1 Chemotherapeutic agents are generally used in
combination with a maximum tolerated dose to eliminate
drug resistance and then to achieve maximum cancer cell
killing.2 However, most patients do not respond to these drugs
and they often experience severe adverse effects because of
greater toxicity compared to each drug alone.3 One of the
major factors responsible for chemoresistance is the evolution
of the tumor cells toward a phenotype that is resistant to
apoptotic cell kill. On a molecular level, increased expression of
the inhibitor of apoptosis protein family (IAPs) has been
detected in this phenotype.4 Therefore, interfering with IAPs
expression or function is a new strategy to eliminate drug
resistance. Survivin, a structurally unique member of the IAP
family that acts as a suppressor of apoptosis and plays a central
role in cell division, is overexpressed in all human cancers, but
demonstrates low expression in normal tissues.5 Several
preclinical studies in different human tumor models have
demonstrated that downregulation of survivin expression or
function, accomplished by means of various strategies, reduced
tumor growth potential, increased the apoptotic rate, and
sensitized tumor cells to chemotherapeutic drugs.6 Heat shock
protein 90 (Hsp90) is a significant target in the development
of rational cancer therapy due to its role at the crossroads of
multiple signaling pathways associated with cell proliferation
and cell viability. Through combined structure- and dynamics-
based computational design strategy and experimental tests,
Meli et al. reported that the nonpeptidic small molecule
5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside
(AICAR) binds the Hsp90 N-domain, destabilizes multiple
Hsp90 client proteins in vivo, including survivin, and exhibits
antiproliferative and proapoptotic activity in multiple tumor cell
lines, while not affecting proliferation of normal human
fibroblasts.7 Doxorubicin (DOX) is a common chemother-
apeutic used in the treatment of a wide range of cancers
because of its excellent antitumor activity.8 Resistance to this
agent impairs treatment of cancer patients and prevents
successful treatment.9 In addition, DOX has a relatively low
therapeutic index and its clinical usage is limited due to acute
and chronic toxicities such as immunosuppression and
cardiotoxicity.10 Therefore, more efficient treatment strategies
must be developed that reduce or eliminate drug resistance,
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decrease the cytotoxic effects of DOX, and also enhance
therapeutic efficacy. Considering the potential value of reducing
or abolishing survivin expression as a means of overcoming
chemoresistance, we have successfully developed a core/shell
type of nanoparticle formulation to codeliver AICAR and DOX,
thereby enhancing antitumor activity while reducing chemo-
resistance.
In recent years, multifunctional particles with magnetism,
fluorescence, and target navigation have been explored exten-
sively in biomedical applications. They have been developed as
an all-in-one biomedical platform for simultaneous fluorescence
imaging, manipulation of cells, and drug delivery tools.11−14
Among the various multifunctional particles, dye-doped silica
magnetic-fluorescent composites are very promising biomedical
materials due to the following advantages: (1) their high
photostability and relatively strong fluorescent signal owing to
their high dye-incorporation capabilities and stabilization in a
protective silica matrix with biocompatibility and less toxicity;
(2) superparamagnetic oxide iron nanoparticles with fast
magnetic response making it easy to manipulate via an external
magnetic field, and this “remote control” providing consid-
erable advantages for many applications;15 (3) contrast agents
with both optical and magnetic contrast serving as good mole-
cular imaging probes both in vitro and in vivo.16 In addition,
active targeting of nanoparticles can potentially increase the
efficacy and reduce the toxicity of therapeutic agents.17 This is
achieved by conjugating the surface of nanoparticles using
specific cell ligands. Folic acid (FA) has been widely used in the
delivery of anticancer agents due to its small size, low cost, high
tumor tissue specificity, nonimmunogenic nature, and fast
internalization through the cellular membrane.18 FA linked
nanocarriers have fairly high binding affinity to folate receptors
(FR) expressed on tumor cells.19
In this study we have rationally designed the bottom-up syn-
thesis of four successive nanoparticles: (1) Fe3O4@SiO2(FITC)-FA
nanoparticles noncontaining any inhibitor or drug; (2) Fe3O4@
SiO2(FITC)-FA/AICAR nanoparticles containing only inhib-
itor; (3) Fe3O4@SiO2(FITC)-FA/DOX nanoparticles contain-
ing only drug; (4) Fe3O4@SiO2(FITC)-FA/AICAR/DOX
nanoparticles containing both inhibitor and drug to evaluate
synergistic potential of therapeutics. The feasibility of nano-
particles was evaluated by investigating their capability in
cellular uptake, fluorescent imaging, and cytotoxic effect in five
different tumor-derived cell lines (A549, HCT-116, HeLa,
Jurkat, and MIA PaCa-2). To the best of our knowledge, this is
the first study which combines AICAR and DOX as therapeutic
agents and examines their synergetic effect within a multifunc-
tional platform. The preliminary cell tests confirm the potential
of these multifunctional nanoparticles as an antitumor treat-
ment in cancer therapy.
Figure 1. Reaction schemes to generate (1) Fe3O4@SiO2(FITC); (2) Fe3O4@SiO2(FITC)-FA/NH2; (3) Fe3O4@SiO2(FITC)-FA/AICAR;
(4) Fe3O4@SiO2(FITC)-FA/DOX; and (5) Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles.
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■ RESULTS AND DISCUSSION
Synthesis and Characterization of Multifunctional
Nanoparticles. To construct the nanoparticles, silica (SiO2)
was used for surface coating of F3O4 particles because dye
molecules can be easily incorporated into a silica shell, and silica
is quite biocompatible and resistant to biodegradation in
biological environments.24 In addition, silica can be easily
surface functionalized for bioconjugation and targeted for
various applications in biological systems. Hence, in this study
we first synthesized bifunctional nanoparticles, F3O4@
SiO2(FITC) (Figure 1) with both fluorescent and magnetic
properties by sol−gel formation of the silica layer onto the
magnetite surface. To increase the cellular uptake of magnetic
iron oxide particles, nanoparticles were vectorized with folic
acid by silanization FA-APTES conjugate on the silica surface
and simultaneously the surfaces were modified with free
APTES to form an amine-terminated overlayer for the sub-
sequent conjugation of both AICAR and DOX via Schiff-base
formation. In general, two different approaches have been
explored for drug transportation by nanoparticles. The first
consists of conjugating the drugs covalently to the nanoparticle
surface through appropriate linkers, and the second in
physically adsorbing or establishing ionic and hydrogen
bonds. The covalent method is the most used because the
bond strength makes nanoparticle−drug conjugates highly
stable.25 Thus, after surface modification with APTES, AICAR
and DOX were covalently linked on the surface of nanoparticles
from their amine group using glutaraldehyde as a linker. In this
step, different concentrations of glutaraldehyde were tested
separately to determine the optimal linker concentration
(Table 1). Among the tested amounts of glutaraldehyde, the
highest coupling yield of AICAR and DOX complexes was
observed at 1% glutaraldehyde concentration. The amount of
bound AICAR or DOX was calculated from the difference
between the amount of AICAR or DOX introduced into the
coupling reaction mixture and the amount of AICAR or DOX
present in the washing water after immobilization by measuring
AICAR or DOX absorbance at 260 and 480 nm, respectively.
The average hydrodynamic diameter of the oleic acid sta-
bilized Fe3O4 nanoparticles, determined for 0.1/0.2/0.4/0.6 mL
concentrations of oleic acid by DLS, were 4.9 ± 1.2, 7.8 ± 1.5,
12.1 ± 3.8, and 18.7 ± 7 nm, respectively. Since oleic acid
effectively regulates Fe3O4 nanoparticle growth and prevents
aggregation, different amounts of oleic acid were tested to
produce size-controlled monodisperse Fe3O4 nanoparticles.
The nanoparticle sizes increased regularly with increasing
amount of oleic acid, due to increased chemisorption of oleate
ions on the magnetite particles. Therefore, we chose the
nanoparticles stabilized with 0.1 mL oleic acid in the next study
to obtain the proper nanoparticles with narrow size distri-
bution. The silica coating led to an increase of the average
particle size (∼17 nm) (Table 2). After the immobilization
process, the size of nanoparticles attached with both AICAR
and DOX increased to approximately 79 nm. Particles with a
diameter ranging from 10 to 100 nm are optimal for intra-
venous injection and have the most prolonged blood circulation
times. These particles are small enough to evade the
Reticuloendothelial System (RES) of the body as well as to
penetrate small capillaries of the tissues and offer the most
effective distribution in targeted tissues.26
The zeta potential of nanoparticles was analyzed to confirm
the change in their surface potential due to proper biofunc-
tionalization. The stepwise conjugation of functional groups on
the silica surface was monitored by measuring the surface
charges at different stages of synthesis (Figure 2 and Table 2).
A negative zeta potential (ζ) value of −17.5 mV (pH 7.4) of
Fe3O4@SiO2(FITC) nanoparticles can be attributed to the
presence of ionizable silanol groups of silica surface. After
modification with APTES/FA conjugate, the zeta potential
value of Fe3O4@SiO2(FITC)-FA/NH2 nanoparticles reverted
to a positive value (+5.3 mV at pH = 7.4) due to the presence
of an excess of positively charged amino groups. FA is expected
to furnish silica surface with negative charge; however, the
excess amount of NH2 groups presumably nullify the FA charge
and make the overall surface charge slightly positive. Further
modification of the surface by conjugating both AICAR or
DOX groups reverted the surface charge back to a negative value,
for Fe3O4@SiO2(FITC)-FA/AICAR, Fe3O4@SiO2(FITC)-FA/
DOX, and Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles
with average values of −9.1, −8.4, and −11.3 mV obtained at
pH = 7.4, respectively. These results could be attributed to a
function of the ionizability of AICAR and DOX groups on silica
surface.
The bulk crystal structure of the nanoparticles was analyzed
by X-ray diffraction (XRD) using the Debye−Scherrer method.
Figure 3 shows the XRD patterns of the Fe3O4 and Fe3O4@
SiO2(FITC) nanoparticles. For Fe3O4 magnetic particles, XRD
spectra showed the six characteristic peaks occurring at 2θ of
30.1, 35.5, 43.1, 53.4, 57.0, and 62.6, which are marked by their
corresponding indices (220), (311), (400), (422), (511), and
(440), respectively. These results were in excellent agreement
with the JCPDS file for Fe3O4 (Card No. #19−629). This
analysis revealed that the prepared magnetic particles are pure
Fe3O4 with a cubic spinel structure. For Fe3O4@SiO2(FITC)
nanoparticles, the same six characteristic peaks corresponding
Table 1. Immobilization Yields of AICAR and DOX on Silica Surface
immobilization method
GA concentration
(%)
AICAR and DOX
immobilization yield (%)
AICAR and DOX immobilization concentration
(μM per mg nanoparticles)
Fe3O4@SiO2(FITC)-FA/AICAR 0.1 6.8 1.3
1.0 30.5 6.1
Fe3O4@SiO2(FITC)-FA/DOX 0.1 10.1 0.2
1.0 51.5 1.0
Fe3O4@SiO2(FITC)-FA/AICAR/DOX 0.1 11.2(AICAR)/10.5(DOX) 2.2(AICAR)/0.2(DOX)
1.0 22.5(AICAR)/35.7(DOX) 4.5(AICAR)/0.7(DOX)
Table 2. Size and Zeta Potential of the Multifunctional
Nanoparticles
nanoparticles size (nm) zeta potential (mV)
Fe3O4@SiO2(FITC) 17.2 ± 3.5 −17.5 ± 1.1
Fe3O4@SiO2(FITC)-FA/NH2 29.7 ± 6.2 +5.3 ± 2.3
Fe3O4@SiO2(FITC)-FA/AICAR 53.5 ± 6.7 −9.1 ± 1.6
Fe3O4@SiO2(FITC)-FA/DOX 62.5 ± 8.6 −8.4 ± 1.5
Fe3O4@SiO2(FITC)-FA/AICAR/DOX 79.2 ± 8.2 −11.3 ± 3.4
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to uncoated Fe3O4 were significantly masked and a broad
peak ranging from 15° to 30° confirmed the presence of an
amorphous silica shell surrounding the Fe3O4 magnetic core.
27
This result indicated that the silica coating did not cause a
phase change in the magnetic particles. Therefore, the magnetic
particles could preserve their magnetic properties for further
applications. Simultaneously, the characteristic peak at 2θ of
18.1° was observed for the fluorescent FITC, which exists in
the silica layer in samples.28
The surface modification and conjugation of nanoparticles
with APTES, FA, AICAR, and DOX were confirmed by Fourier
transform infrared (FTIR) spectroscopy. For comparison,
Figure 2. Zeta potential measurements of (1) Fe3O4@SiO2(FITC); (2) Fe3O4@SiO2(FITC)-FA/NH2; (3) Fe3O4@SiO2(FITC)-FA/AICAR;
(4) Fe3O4@SiO2(FITC)-FA/DOX; and (5) Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles obtained at pH = 7.4 using DLS.
Figure 3. Powder XRD patterns of Fe3O4 and Fe3O4@SiO2(FITC) nanoparticles. The position of the peak of FITC and the broad peak of
amorphous silica are marked with a red arrow and asterisk (*), respectively.
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Figure 4. FTIR characterization of (A) Fe3O4, Fe3O4@SiO2(FITC), Fe3O4@SiO2(FITC)-FA/NH2; (B) Fe3O4@SiO2(FITC)-FA/AICAR,
Fe3O4@SiO2(FITC)-FA/DOX, and Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles.
Figure 5. TGA trace of Fe3O4@SiO2(FITC) and Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles.
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FTIR spectra of (1) Fe3O4, (2) Fe3O4@SiO2(FITC), (3)
Fe3O4@SiO2(FITC)-FA, (4) Fe3O4@SiO2(FITC)-FA/AICAR,
(5) Fe3O4@SiO2(FITC)-FA/DOX, and (6) Fe3O4@
SiO2(FITC)-FA/AICAR/DOX nanoparticles are shown in
Figure 4a/b.
The two oxygen atoms of COO in oleic acid provide
two coordination positions to form the chemical interaction
with Fe atom. As a result of the chemical interaction, the band
1710 cm−1, which is assigned to the stretching vibration of
CO in free oleic acid, disappeared in the FTIR spectra of
Fe3O4 and the asymmetric (−COO−) and symmetric (−COO−)
stretch vibration band resulted at 1430 and 1520 cm−1,
respectively. The bands at 2853 and 2924 cm−1 are attributed
to the asymmetric CH2 stretch and the symmetric CH2 stretch
Figure 6. SEM images and size distribution of (a) Fe3O4, (b) Fe3O4@SiO2(FITC), (c) Fe3O4@SiO2(FITC)-FA/NH2, and STEM images of
(d) Fe3O4@SiO2(FITC)-FA/AICAR, (e) Fe3O4@SiO2(FITC)-FA/DOX, (f) Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles.
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in oleic acid, confirm the presence of the oleic acid on the
Fe3O4 surface.
29 The spectrum of Fe3O4 nanoparticles exhibited
a strong peak at 584 cm−1 which is assigned to typical Fe−O
vibrations of the magnetite structure, sustaining the iron oxide
identification by XRD.30
In the FTIR spectra of Fe3O4@SiO2(FITC), new bands
associated with Si−O−Si asymmetric stretching at 1070 cm−1,
Si−OH stretching at 950 cm−1, Si−O−Si symmetric stretching
at 794 cm−1, and Si−O−Si bending vibrations at 467 cm−1 were
observed, thus confirming the formation of the silica shells.31
The broad band around 3425 cm−1 was due to O−H stretching
vibrations of adsorbed water and hydrogen-bonded surface
silanol groups, whereas the bands around 1548 and 1632 cm−1
are attributed to bending of N−H, characteristic of the pres-
ence of an NH2 group.
32 Furthermore, a significant decrease
in the intensity of the bands related to Fe−O vibrations at
580 cm−1, revealing an increase in the thickness of the silica
shells and the complete encapsulation of the magnetic cores, in
accordance with the results from XRD and EDX.
The band at 1606 cm−1 corresponding to the stretching
vibrations of CC in the backbone of the aromatic ring
present in folic acid, indicated the immobilization of folic acid
on nanoparticle surfaces. The peak at 1534 cm−1 is due to the
primary amine group of APTES, indicating that the nano-
particles have been surface modified by amine group. The band
at 1585 cm−1, referred to as the stretching vibration of two
carbonyl groups of the anthracene ring of DOX,33 indicated
that DOX was successfully attached to the surface of the
nanoparticles. The spectral range between 1000 and 800 cm−1
is very informative on nucleic acid absorption, due to sugar
vibrations sensitive to their conformation and to backbone
vibrational modes. Therefore, the bands at 890 and 926 cm−1
indicated that AICAR immobilization with covalent bonding on
the surface of the nanoparticles was successfully achieved.34
The grafting density of FA, AICAR, and DOX on nano-
particles was analyzed by measuring the differences of weight loss
due to organics decomposition in both Fe3O4@SiO2(FITC)
and Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles, by
TGA (Figure 5). According to the results, the decreased weight
of Fe3O4@SiO2(FITC) nanoparticles was about 7.77% between
25 and 650 °C, presumably due to the degradation of the organic
fluorescent FITC within silica layer. Fe3O4@SiO2(FITC)-FA/
AICAR/DOX nanoparticles showed a weight loss of 21.20 wt %
and exhibited a four-stage weight loss process in the same
temperature range, which could be attributed to the presence
of substantial amount of FA, AICAR, and DOX molecules.
The notable difference (13.43 wt %) between the mass loss of
Fe3O4@SiO2(FITC) and Fe3O4@SiO2(FITC)-FA/AICAR/
DOX nanoparticles revealed the successful surface conjugation
of the nanoparticles with FA, AICAR, and DOX.
The exterior morphologies and interior structures of the
nanoparticles at different fabrication stage were investigated
by SEM and STEM, respectively; and the related chemical
compositions were determined by EDX.
SEM images showed that the parent iron oxide nanoparticles
were nearly spherical and present a narrow size distribution
(Figure 6a/b/c). The corresponding EDX spectrum confirmed
that the Fe3O4 particles are composed of Fe and O, with the C
peak indicating the presence of a thin oleic acid shell
enveloping the magnetic cores, without any impurity. The
untagged Al peak is from the double stick aluminum tape used in
sample preparation (Figure 7a and Table 3). After the silica
coating, Fe3O4@SiO2(FITC) and Fe3O4@SiO2(FITC)-FA/NH2
nanoparticle morphology remained unchanged. EDX analysis
Figure 7. EDX spectra of (a) Fe3O4, (b) Fe3O4@SiO2(FITC), (c) Fe3O4@SiO2(FITC)-FA/NH2, (d) Fe3O4@SiO2(FITC)-FA/AICAR,
(e) Fe3O4@SiO2(FITC)-FA/DOX, and (f) Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles (inset: weight percentages of composition),
obtained during SEM experiments.
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confirmed the existence of Si, a gradual increase in the N
content, and a significant decrease in the Fe content, which was
still detected due to the penetration depth of the X-ray beam,
thus confirming the encapsulation of the magnetic cores in a
thick silica shell (Figure 7b/c). The EDX analysis of Fe3O4@
SiO2(FITC)-FA/AICAR, Fe3O4@SiO2(FITC)-FA/DOX, and
Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles clearly
showed the progressive increase in C content and reduction
in N content on the silica surfaces due to organic functionalities
which are gradually enriched by iterative chemical conjugation
(Figure 7d/e/f).
The morphologies of the Fe3O4@SiO2(FITC)-FA/AICAR,
Fe3O4@SiO2(FITC)-FA/DOX, and Fe3O4@SiO2(FITC)-FA/
AICAR/DOX nanoparticles were investigated by STEM.
Figure 6d/e/f shows that the nanoparticles have core−shell
morphology and spherical shape without aggregation or
accumulation.
Table 3. Surface Atomic Percentages of the Nanoparticles,
Obtained from EDX Spectra
atomic (%)
nanoparticles O Si C N Fe
Fe3O4 51.6 - 37.4 - 11.0
Fe3O4@SiO2(FITC) 56.9 22.4 15.1 5.1 0.5
Fe3O4@SiO2(FITC)-FA/NH2 57.5 17.9 17.4 6.9 0.3
Fe3O4@SiO2(FITC)-FA/AICAR 56.1 13.1 26.3 3.8 0.7
Fe3O4@SiO2(FITC)-FA/DOX 53.7 14.6 25.8 5.2 0.7
Fe3O4@SiO2(FITC)-FA/AICAR/DOX 55.5 14.7 25.5 3.5 0.8
Figure 8. Intracellular localization of the Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles in cancer cells. For rows: A, bright-field images; B,
fluorescence images; C, the merger of both. For columns: 1, A549; 2, HCT-116; 3, HeLa; 4, Jurkat; and 5, MIA PaCa-2 cells.
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Cellular Uptake. Specificity and cellular accumulation of
Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticle vectors by
five tumor-derived cell lines (A549, HCT-116, HeLa, Jurkat,
and MIA PaCa-2) were confirmed by fluorescence microscopy,
which demonstrated intracellular nanoparticle accumulations in
each cell line (Figure 8 plots 1−5, rows a−c). The weak green
fluorescence in the cytoplasm clearly indicated the successful
penetration of the vectors into the cells via folate-receptor-
mediated endocytosis. Verification of cellular accumulation of the
vectors was obtained by comparing of the fluorescence images
with the corresponding bright-field images. The overlay images
demonstrated that the magnetic-fluorescent vectors represent a
true molecular targeting. These results corroborated the
overexpression of folate receptor on A549, HCT-116, HeLa,
Jurkat, and MIA PaCa-2 cells, which facilitate the recognition of
nanoparticles and increase the uptake through internalization.35
Cytotoxicity of the Multifunctional Nanoparticles. To
examine how the conjugation of AICAR with DOX affected its
cytotoxicity, we compared the proliferation of A549, HCT-116,
HeLa, Jurkat, and MIA PaCa-2 cells treated with the
nanoparticle complexes using MTT cell proliferation assay.
First, we chose a concentration of DOX (20 μM) 10 times
lower than the concentration of AICAR (200 μM) during
immobilization processes in terms of minimal growth inhibition
in these cells for our combination therapy studies. Next, we
investigated whether combination therapy with the inhibitor
and drug would be effective at inhibiting tumor cell prolifera-
tion and inducing cell death. Cancer cells were exposed to
nanoparticles with increasing concentrations of nanoparticles
(0.1−200 μg/mL) for 48 h. Among all nanoparticles tested,
Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles showed
the lowest IC50 value in A549 cells and led to approximately
1.8-fold decreases in the IC50 values to Fe3O4@SiO2(FITC)-
FA/DOX nanoparticles that would be significant in a clinical
context (Table 4). The conjugation of AICAR with DOX
improved the cytotoxicity not only with a synergistic inhibition,
but also with a 30% decreased level of DOX in Fe3O4@
SiO2(FITC)-FA/AICAR/DOX nanoparticles. Fe3O4@
SiO2(FITC)-FA/AICAR nanoparticles showed low cytotoxicity
to all the cells tested, whereas Fe3O4@SiO2(FITC)-FA control
nanoparticles did not affect cancer cell viabilities to the same
extent (Figure 9). These data showed that Fe3O4@SiO2(FITC)-
FA/AICAR/DOX nanoparticles were more effective against
A549 and HeLa cells while HCT-116, Jurkat, and MIA PaCa-2
had similar IC50 values. These results indicate that survivin
inhibition by AICAR can increase the efficacy of chemotherapy
for a wide range of cancer types, which may have important
implications for the design of experimental protocols.
We also observed a clear dose-dependent inhibition
with Fe3O4@SiO2(FITC)-FA/AICAR/DOX and Fe3O4@
SiO2(FITC)-FA/DOX nanoparticles in all the cancer cells
tested. These nanoparticles strongly reduced the proliferation
of cancer cells after 48 h of treatment, while a low effect was
observed with Fe3O4@SiO2(FITC)-FA/AICAR nanoparticles
and no significant effect of the control Fe3O4@SiO2(FITC)-FA
nanoparticles. The poor antitumoral efficacy exhibited by
Fe3O4@SiO2(FITC)-FA/AICAR indicates that the maximum
amount of these nanoparticles in the cells was not sufficient to
affect cell viability. This implies that a higher concentration
of the nanoparticles would be needed to obtain a notable
reduction in cell viability.
As survivin is not a cell surface protein and does not have an
intrinsic enzymatic activity, targeting of survivin for therapeutic
purposes has been mostly employed at the transcriptional
levels.6 A number of siRNA-based therapies have been reported
as survivin neutralizing agent to increase the sensitivity of
cancer cells to DOX and have managed to restore sensitivity to
chemotherapeutically induced apoptosis in several cancer
cells.36,37 However, one of the main hurdles to the application
of siRNA-based therapy identified to date is the potential off-
target effects. It has been well-documented that delivering
siRNA into cells can suppress the expression of genes other
than the desired targets.38 To eliminate these obstacles, AICAR
could be of potential value for increasing the sensitivity of
cancer cells to anticancer drugs, as a small-molecule inhibitor
that could be easily incorporated in practice for the down-
regulation of survivin.
■ CONCLUSIONS
Herein we presented successful fabrication and characterization
of novel magnetic-fluorescence based, folic acid functionalized
nanoparticles for simultaneous delivery of AICAR and DOX
into cancer cells. These multifunctional nanoparticles were
synthesized by a simple coprecipitation of Fe2+/Fe3+ salts which
were then encapsulated within a SiO2 shell to provide surface
modification and biocompatibility as well as to act as a host for
fluorescent dye (FITC). The cancer targeting feature was
endowed by conjugating FA on the surface of nanoparticles via
an esterification reaction. AICAR and DOX complexes were
then successfully attached on the amine-functionalized nano-
particles using Schiff-base chemistry. As far as we know, the
synergetic effect of AICAR and DOX has not yet been
investigated and this is the first successful preparation of
AICAR-DOX conjugated luminomagnetic nanoparticles as a
single platform. The structures of the newly synthesized
nanoparticles have been confirmed by different characterization
techniques: DLS; XRD; FTIR; TGA; EDX; SEM; and STEM.
The nanoparticles possess high inhibitor and drug association
with good biocompatibility. In addition, the preparation proce-
dure is an environmentally friendly and low-cost synthetic route.
The combination of AICAR and DOX is expected to
maximize tumor cell killing by sensitization of cancer cells and
Table 4. IC50 values of Fe3O4@SiO2(FITC)-FA, Fe3O4@SiO2(FITC)-FA/AICAR, Fe3O4@SiO2(FITC)-FA/DOX, and
Fe3O4@SiO2(FITC)-FA/AICAR/DOX Nanoparticles in A549, HCT-116, HeLa, Jurkat, and MIA PaCa-2 Cells When
Incubated for 48 ha
nanoparticles (μg/mL) A549 HCT-116 HeLa Jurkat MIA PaCa-2
Fe3O4@SiO2(FITC)-FA N.A. N.A. N.A. N.A. N.A.
Fe3O4@SiO2(FITC)-FA/AICAR N.A. N.A. N.A. N.A. N.A.
Fe3O4@SiO2(FITC)-FA/DOX 26.4 ± 1.4 48.0 ± 4.8 61.2 ± 6.1 41.7 ± 2.9 48.7 ± 3.8
Fe3O4@SiO2(FITC)-FA/AICAR/DOX 14.8 ± 4.1 49.5 ± 3.0 47.5 ± 2.5 48.2 ± 3.1 58.0 ± 5.2
aN.A. = Not Applicable (the data cannot be fitted as no enough inhibition is observed) in the cancer cells. Values represent the mean ± SD of three
independent experiments.
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to minimize organ toxicity by targeting administration of the
inhibitor and drug complex. Fluorescence microscopy and
MTT studies confirmed intracellular nanoparticle accumulation
and efficient antitumor activity. We have shown that the cancer
cells can be visualized with a low concentration of Fe3O4@
SiO2(FITC)-FA/AICAR/DOX nanoparticles (10 μg/mL) with
Figure 9. Anticancer activities of Fe3O4@SiO2(FITC)-FA, Fe3O4@SiO2(FITC)-FA/AICAR, Fe3O4@SiO2(FITC)-FA/DOX, and Fe3O4@
SiO2(FITC)-FA/AICAR/DOX nanoparticles against A549, HCT-116, HeLa, Jurkat, and MIA PaCa-2 cells after 48 h of growth. The results are
expressed as percentage of cell viability or cell number obtained in the untreated controls. The nanoparticle concentrations are expressed as μg
nanoparticles per mL. Fe3O4@SiO2(FITC)-FA blank nanoparticles were used as control. Each column represents the mean ± SD of three
independent experiments performed in triplicate normalized to nontreated cells (taken as 100%). Note that the amount of DOX conjugation on the
surface of Fe3O4@SiO2(FITC)-FA/AICAR/DOX nanoparticles is 30% less than the surface of Fe3O4@SiO2(FITC)-FA/DOX nanoparticles.
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detectable cell numbers about 105 confirming cellular uptake of
nanoparticles. Moreover, the nanoparticles not only served as a
nanocarrier but also exhibited synergistic cytotoxic activity
against the cancer cells. We have demonstrated that
combination therapy with Fe3O4@SiO2(FITC)-FA/AICAR/
DOX nanoparticles is superior to monotherapy with nano-
particles decorated with either AICAR or DOX alone.
Importantly, the combination effects of the nanoparticles
were confirmed in five different cancer cell lines. Our data
indicate a strong effect of Fe3O4@SiO2(FITC)-FA/AICAR/
DOX nanoparticles on the lung carcinoma A549 and the
cervical carcinoma HeLa cell lines, while similar outcomes were
observed on the colon carcinoma HCT-116, the leukemia
Jurkat, and the pancreatic carcinoma MIA PaCa-2 cell lines.
We believe that this combination will be a valuable addition in
the sensitization of cancer cells toward anticancer drugs to
improve the therapeutic outcome of chemotherapy. Finally, it
could be concluded that coadministration of AICAR and DOX
might promote apoptosis more than each drug alone or
incubation of one compound prior to the other one. The
characterization of apoptotic and antiproliferative effects and
related caspase-3 activity studies of the nanoparticles are
currently under investigation.
■ MATERIAL AND METHODS
Materials. Iron(II) chloride tetrahydrate (FeCl2·4H2O)
(99%), iron(III) chloride hexahydrate (FeCl3·6H2O) (98%),
3-aminopropyltriethoxysilane (APTES), tetraethyl orthosilicate
99.9% (TEOS), N-hydroxysuccinimide (NHS), N,N-dicyclo-
hexyl-carbodiimide (DCC), fluorescein isothiocyanate (FITC),
folic acid (FA), dimethyl sulfoxide (DMSO), triton X-100, FT-
IR grade potassium bromide ≥99% (KBr), Glutaraldehyde 25%
aqueous solution, 5-aminoimidazole-4-carboxamide-1-β-D-ribo-
furanoside ≥98% (AICAR), and 3-[4,5-dimethyl-2-thialzolyl]-
2,5-diphenyltetrazolium bromide (MTT) were purchased from
Sigma-Aldrich Chemicals. Oleic acid (99%), cyclohexane,
1-hexanol (>98%), ammonium hydroxide 25% aqueous
solution, and toluene were purchased from Fluka/Riedel-de
Haen̈ Chemicals. Doxorubicin was obtained from SABA
Pharma. DMEM growth medium, RPMI-1640 growth medium,
10% fetal bovine serum (FBS), streptomycin, penicillin, and
L-glutamic acid were purchased from Gibco Life Technologies.
All other chemicals and reagents were of the highest purity. All
the experiments were performed in deionized Milli-Q water.
Cell Cultures. A549 (human epithelial lung carcinoma),
HCT-116 (human epithelial colorectal carcinoma), HeLa
(human epithelial cervical carcinoma), Jurkat (human acute
T-cell leukemia), and MIA PaCa-2 (human epithelial pancreatic
carcinoma) cell lines were kindly provided by Biotechnology
and Bioengineering Research and Application Centre, Izmir
Institute of Technology, Turkey. A549, HCT-116, HeLa, and
MIA PaCa-2 cancer cells were cultured in Dulbecco’s modified
Eagle medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 100 μg/mL streptomycin, 100 U/mL penicillin,
and 2 mM L-glutamic acid; Jurkat cancer cells were cultured in
Roswell Park Memorial Institute-1640 (RPMI-1640) growth
medium supplemented with 10% fetal bovine serum (FBS),
100 μg/mL streptomycin, 100 U/mL penicillin, and 2 mM
L-glutamic acid. All cell lines were incubated in 5% CO2 and
90−100% relative humidity at 37 °C. Medium renewal was
carried out 2 to 3 times per week, and cells were subcultured
when they achieved 80−90% confluence. All cell lines were
discarded after 20 generations, and new lines were obtained
from frozen stocks.
Synthesis of Multifunctional Nanoparticles. Synthesis
of Oleic Acid Coated Fe3O4 Nanoparticles. Oleic acid
coated iron oxide (Fe3O4) nanoparticles were synthesized by
coprecipitation of Fe2+ and Fe3+ salts with a stoichiometric ratio
of 1:2 in accordance with the chemical reaction formula:
[Fe2+ + 2Fe+3 + 8OH− = Fe3O4 + 4H2O]. Since oleic acid
effectively regulates Fe3O4 nanoparticles growth and prevents
aggregation,20 in this step we determined the oleic acid
concentration to obtain surfactant-stabilized and narrow size
distributed Fe3O4 nanoparticles. First, 0.456 g FeCl3·6H2O and
0.189 g FeCl2·4H2O were dissolved in 100 mL ultrapure water
under nitrogen environment with ultrasonification for 10 min.
NH4OH (25%) aqueous solution was added dropwise until
pH 10−11. After base had been added, the alkaline solution
started to became dark brown. Oleic acid (0.1/0.2/0.4/0.6 mL)
was added immediately to the dark brown solution and the
resulting emulsion was aged, under vigorous mechanical
stirring, at room temperature for 1 h. Then the emulsion was
heated up to 95 °C to convert iron hydroxides into magnetite.
As soon as that temperature was reached, the suspension was
cooled down to room temperature. The mixture was then
acidified to pH 5−6 by using a HNO3 solution (35%) to
promote the chemisorption of oleate ions on the magnetite
particles. Consequently, the particles coagulated and precipi-
tated in the solution due to the hydrophobicity provided by the
oleate layer. The resulting magnetic particles settled within a
few minutes and were then washed with ultrapure water four
times to remove the unreacted salts and with ethanol three
times to remove water and nonadsorbed oleic acid. Finally, the
oleic acid coated nanoparticles were dried in vacuum oven at
room temperature for 12 h.
Synthesis of Fe3O4@SiO2(FITC) Nanoparticles. Silica core−
shell nanoparticles [Fe3O4@SiO2(FITC)] were synthesized by
a water-in-oil reverse micelle method with some modification of
a published procedure in two steps.21 In the first step, the oleic
acid protected Fe3O4 nanoparticles were coated with a thin
silica shell by hydrolysis and condensation of TEOS as sol−gel
precursor. Briefly, a microemulsion system was prepared with
10 mg of dried magnetic Fe3O4 powder added to 0.3 mL
TEOS, 70 mL cyclohexane, 20 g Triton X-100 (as surfactant),
15 mL n-hexanol (as cosurfactant), and 3.7 mL H2O mixture
with intense stirring at room temperature. Six hours later,
1.0 mL aqueous NH4OH (25%) was introduced dropwise to
initiate TEOS hydrolysis and the microemulsion was kept
stirring for another 24 h. In the second step, after the first silica
shell had been coated on the magnetic core, the dye molecules
were encapsulated into the second silica shell to enhance
photochemical stability. FITC-APTES conjugate was prepared
by covalently attaching FITC to the APTES silane compound
by a stable thiourea linkage. Briefly, 1.0 mg FITC and 0.15 mL
APTES were combined together in 0.2 mL of absolute ethanol
under nitrogen atmosphere and stirred in orbital shaker for
24 h. The FITC-APTES conjugate solution was protected from
light during reaction and storage to prevent photobleaching.
After 24 h, FITC-APTES ethanolic solution and 0.3 mL TEOS
were added to the first microemulsion under stirring in dark for
24 h. Finally, ethanol was added to destabilize the micro-
emulsion system. The FITC-incorporated silica-coated core−
shell [Fe3O4@SiO2(FITC)] nanoparticles were collected via
centrifugation and washed in sequence with ethanol and
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ultrapure water to remove any surfactant and unreacted
reactants and dried by air.
Synthesis of Fe3O4@SiO2(FITC)-FA/NH2 Nanoparticles. The
Fe3O4@SiO2(FITC)-FA/NH2 nanoparticles were prepared
according to a literature procedure with some modification.22
First, folic acid was conjugated with APTES by an esterification
reaction of the carboxyl group with the amine group. In brief,
an APTES ester of FA (FA-APTES) was prepared by mixing
folate (4.0 mg) with APTES (2.0 μL) in 40 mL dry dimethyl
sulfoxide (DMSO) in the presence of NHS (1.1 mg) and DCC
(4.7 mg) as the catalyst at room temperature for 2 h. After this,
a mixture of Fe3O4@SiO2(FITC) nanoparticles (100 mg),
FA-APTES conjugate, and free APTES (17 μL) in toluene
(160 mL) was stirred at room temperature for 24 h to
introduce FA-APTES conjugate and free APTES (to provide a
linker for the subsequent conjugation of both AICAR and
DOX) on the surface of silica-coated nanoparticles by
hydrolysis and condensation of APTES through silanization.
Final products were collected by a magnet, washed with toluene
and ethanol several times to remove any unreacted reactants,
and dried in a vacuum oven at room temperature, overnight.
Synthesis of Fe3O4@SiO2(FITC)-FA/AICAR/DOX Nanopar-
ticles. Fe3O4@SiO2(FITC)-FA/AICAR/DOX were prepared
by coupling of AICAR and DOX complexes on the surface of
amine-modified nanoparticles via glutaraldehyde activation. In
this step three successive nanoparticles were synthesized to
evaluate the synergistic potential of therapeutics: (1) Fe3O4@
SiO2(FITC)-FA/AICAR nanoparticles containing only inhib-
itor; (2) Fe3O4@SiO2(FITC)-FA/DOX nanoparticles con-
taining only drug; (3) Fe3O4@SiO2(FITC)-FA/AICAR/DOX
nanoparticles containing both inhibitor and drug. Furthermore,
since glutaraldehyde is a very reactive reagent,23 different
concentrations of glutaraldehyde were tested separately to
determine the optimal linker concentration. First of all, the
surface of Fe3O4@SiO2(FITC)-FA/NH2 nanoparticles (10 mg)
was activated with glutaraldehyde (0.1−1.0%) in 20 mL
ultrapure water under vigorous mechanical stirring at room
temperature for 30 min. Then, nanoparticles were collected via
centrifugation and the unreacted glutaraldehyde was removed
by comprehensive washing with ultrapure water. Glutaralde-
hyde activated nanoparticles were subsequently incubated with
AICAR (200 μM) and DOX (20 μM) complexes in 20 mL
ultrapure water under vigorous mechanical stirring at room
temperature for 6 h. For AICAR and DOX conjugation, an
excess amount of AICAR (molar ratio of AICAR to DOX = 10)
was used to evaluate the sensitization effect of AICAR with low-
dose DOX concentration. The resulting nanoparticles [(1)
Fe3O4@SiO2(FITC)-FA/AICAR; (2) Fe3O4@SiO2(FITC)-
FA/DOX; (3) Fe3O4@SiO2(FITC)-FA/AICAR/DOX] were
magnetically separated and washed with ultrapure water several
times to remove any unreacted reactants and dried under
vacuum at room temperature, overnight.
Structural and Physicochemical Characterization.
Dynamic light scattering (DLS) measurements were performed
at 25 °C, using a Malvern Zetasizer NanoZS compact scattering
spectrometer. The average hydrodynamic diameters, the size
distributions and the surface charge analysis of the samples
were determined using Malvern Dispersion Technology
Software 7.11. Nanoparticles were suspended in ultrapure
water (Fe3O4 nanoparticles in hexane) to give optimum signal
intensity. All measurements were repeated three times to verify
the reproducibility of the results.
Powder X-ray diffraction (XRD) measurements were
performed with “Philips X’Pert Pro”, at room temperature by
using Cu Kα radiation (λ = 1.5405 Å) and Bragg−Brentano
θ/2θ configuration. The measurements were performed over
the 2θ range of 15−70°.
The Fourier transform infrared spectroscopy (FTIR) spectra
of the nanoparticles were collected with a “PerkinElmer
Spectrum-100” spectrophotometer in the range 450−
4000 cm−1. The spectra of the dried samples were obtained
by employing a KBr pellet.
Thermogravimetric analysis (TGA) was performed on a
PerkinElmer Diomand TG/DTA Instruments from room
temperature to 650 °C with a heating rate of 10 °C/min in a
nitrogen flow.
Scanning electron microscopy (SEM) and energy-dispersive
X-ray spectroscopy (EDX) studies were performed at a high
resolution environmental scanning electron microscope (FEI
Quanta 250 FEG) equipped with an energy-dispersive X-ray
spectrometer (Oxford AZtec). Prior to examination, the
lyophilized nanoparticles were placed on a double stick tape
over aluminum stubs to get a uniform layer of particles.
Scanning transmission electron microscopy (STEM) images
of the final nanoparticles were obtained with a “FEI Quanta
250 FEG” microscope operating with STEM Detector. The
nanoparticles were dispersed in water under sonication and a
drop was placed on a carbon-coated 400 mesh copper grid
followed by air-drying.
Cellular Uptake Analysis. Internalization of the nano-
particles was visualized using an Olympus IX2-ILL100
fluorescence microscope equipped with an appropriate filter
set. Images were acquired using a CCD camera and analyzed
using ImageJ advanced version software. A549, HCT-116,
HeLa, Jurkat, and MIA PaCa-2 cells (1 × 105 cells/well) were
seeded in 12-well plates overnight before experiments. Fe3O4@
SiO2(FITC)-FA/AICAR/DOX nanoparticles were added into
the incubation medium at concentrations of 10 μg/mL for 4 h
incubation in 5% CO2 at 37 °C. All cells except Jurkat
(suspension cells) and MIA PaCa-2 (suspension/adherent
mixed cells) were washed twice with phosphate-buffered saline
(PBS). Microscopic images in the green channel for detection
of the FITC label encapsulated in nanoparticles and in the
bright-field were obtained by fluorescence microscopy.
Cytotoxicity of Multifunctional Nanoparticles. The
cytotoxicity of the prepared nanoparticles were evaluated by
3-(4,5-dimethylthialzol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. A549, HCT-116, HeLa, Jurkat, and MIA
PaCa-2 cells were seeded into 96-well plates at a density of
1 × 104 per well in 100 μL of media and grown overnight. The
cells were then incubated with various concentrations (0.1/1.0/
10/50/100/200 μg/mL) of nanoparticles for 48 h at 37 °C
under 5% CO2. Following this incubation, cells were incubated
in medium containing 0.5 mg/mL of MTT for 4 h. The
medium was discarded, and the precipitated formazan violet
crystals were dissolved in 150 μL of DMSO to solubilize the
formazan. After shaking the plate for 10 min, the absorbance of
the sample was measured at 570 nm by multidetection
microplate reader. The absorbance of dissolved formazan in
the visible region correlates with the number of intact active
cells. The cytotoxicity was evaluated with reference to the IC50
value that was defined as the concentration needed for a 50%
reduction of survival based on the survival curves. IC50 values
were calculated from dose−response curves (nanoparticle con-
centration vs cell survival fraction) obtained in multireplicated
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experiments. For the combination treatment studies, the cells
were incubated with (1) Fe3O4@SiO2(FITC)-FA blank nano-
particles as control, (2) Fe3O4@SiO2(FITC)-FA/AICAR nano-
particles containing only inhibitor, (3) Fe3O4@SiO2(FITC)-
FA/DOX nanoparticles containing only drug, or (4) Fe3O4@
SiO2(FITC)-FA/AICAR/DOX nanoparticles containing both
inhibitor and drug to test the efficacy of nanoparticles on cancer
cell growth.
Statistical Analysis. All data were represented as means ±
standard deviation (SD). Statistical analysis was performed with
the Student’s t test, using Excel Software (Microsoft). A P value
of ≤0.05 was considered statistically significant.
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